The study found that 95% of healthcare workers have worked while sick, most often because the symptoms were mild or began during their work shift.
In the hospital setting, there are multiple contributing factors that can drive C. diff infections. The lead author of the recent research, which was published in The Joint Commission Journal on Quality and Patient Safety, said the main drivers of C. diff infections are likely to vary from hospital to hospital.
The APIC conference aims to provide infection preventionists, physicians, researchers, epidemiologists, educators, administrators, and medical technologists with strategies that can be implemented immediately to improve prevention programs and make healthcare safer.
The recent research published in CHEST associated each additional hour from emergency room arrival to antibiotic administration to 10% increased odds of 1-year mortality.
The data has prompted the CDC to encourage hospitals to take action in defense against outbreaks of bacterial infections such as methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA).
Aspergillus is a common type of mold that poses a low risk to surgical patients, but Seattle Children’s is contacting about 3,000 patients who underwent procedures in the past four months.
Among other infection control practices for hemodialysis, surveyors will be observing water and dialysate testing, medication storage, preparation and administration, and “patient placement in full view of staff during dialysis treatment,” according to a Joint Commission official.
The CDC issued a bulletin urging hospitals and other healthcare facilities to remain prepared for infectious disease outbreaks.
The recent research found only 46% of emergency department sepsis patients received antibiotics within 3 hours of ED arrival when the emergency room was crowded compared to 63% receiving timely antibiotics when the ER was not crowded.
The HHS Division of Research, Innovation, and Ventures (DRIVe), which operates under the Biomedical Advanced Research and Development Authority (BARDA), is seeking medical product developers, research teams, and companies offering disruptive solutions to health security threats.